Philips has launched Transcend Plus, the next-generation 2D and 3D imaging and intelligent automation software for its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems.
The new offering, which recently received the US Food and Drug Administration (FDA) clearance, is designed to improve image quality and introduce AI enhancements.
The advancements aim to address the increasing complexities in cardiac care delivery.
Transcend Plus introduces significant improvements in 2D and 3D imaging, enhancing sharpness and contrast.
The enhancements support the superior visualisation of cardiac anatomy, delivering diagnostic accuracy in complex cases.
The update also adds a feature called 2D Auto EF Advanced, expanding AI capabilities for more accurate cardiac function assessments.
Philips cardiology ultrasound business leader David Handler said: “Transcend Plus represents a bold leap forward in the evolution of echocardiography, reinforcing our commitment to continuous innovation, empowering clinicians with AI-driven tools that enhance confidence, accelerate decision-making, and elevate care at every stage of the cardiac journey.
“Transcend Plus is more than an advancement; it’s a clear statement of Philips’ leadership in cardiovascular ultrasound.
“Building on the momentum of our original Transcend launch, Transcend Plus brings the full power of AI integration to the forefront, giving clinicians the confidence, speed, and precision they need to lead in cardiac care, today and into the future.”
Philips added 26 FDA-approved AI applications into Transcend Plus, including 2D Auto EF and 2D Auto EF Advanced, to simplify clinical workflows and enhance diagnostic accuracy.
The enhancements are applicable across various care settings, improving consistency and confidence in patient assessments.
Transcend Plus supports the left ventricular function assessment with fast and reproducible results, aiding cardiologists in evaluating LV function consistently.
Automated tools reduce operator variability, crucial in high-pressure clinical settings.
Features like 2D Auto EF Advanced enhance assessments in non-contrast imaging scenarios, broadening clinical applicability.
Transcend Plus empowers clinicians with sharper imaging and intelligent automation, facilitating faster and informed decision-making.
It offers enhanced image quality, advanced AI integration, and actionable insights, aiding in managing patient volumes efficiently without compromising on diagnostic quality.
Recently, Philips unveiled its plans to invest over $150m in US manufacturing and research and development (R&D) to enhance its AI-powered health technology offerings.
The initiative builds on Philips’ existing $900m annual R&D investment in the US to bolster local manufacturing capabilities.
